Clinical trials in Vienna – page 49

838 clinical trials in Vienna, Austria across 10 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Vienna at a glance

838

clinical trials

Research sites10

Quick filters

838 trials in Vienna

Open in trial search

Plasma cell myeloma

Not recruiting

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Hidradenitis

Not recruiting

Study of Lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational

Study of Lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Lutikizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Fabry's disease

Not recruiting

Study on Long-Term Safety of Oral Lucerastat for Adults with Fabry Disease

InvestigationalNo placebo

Study on Long-Term Safety of Oral Lucerastat for Adults with Fabry Disease

InvestigationalNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Lucerastat
Sponsor:Idorsia Pharmaceuticals Ltd.

Contact Research Centre

Central nervous system lymphoma

Not recruiting

Study on De-escalated Induction Therapy with Methotrexate, Cytarabine, Thiotepa, and Rituximab for Newly Diagnosed Primary CNS Lymphoma Patients

Registered drugNo placebo

Study on De-escalated Induction Therapy with Methotrexate, Cytarabine, Thiotepa, and Rituximab for Newly Diagnosed Primary CNS Lymphoma Patients

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Busulfan
Sponsor:Klinikum Der Landeshauptstadt Stuttgart gKAöR

Contact Research Centre

Glomerulonephritis membranoproliferative+1

Not recruiting

Study on the Effectiveness and Safety of Pegcetacoplan for Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Registered drug

Study on the Effectiveness and Safety of Pegcetacoplan for Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Registered drug

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Pegcetacoplan
Sponsor:Apellis Pharmaceuticals Inc.

Contact Research Centre

B-cell lymphoma

Not recruiting

Study of Rituximab, Polatuzumab Vedotin, and Glofitamab for Untreated Aggressive B-cell Lymphoma in Patients Over 60 Not Eligible for Full R-CHOP

Registered drugNo placebo

Study of Rituximab, Polatuzumab Vedotin, and Glofitamab for Untreated Aggressive B-cell Lymphoma in Patients Over 60 Not Eligible for Full R-CHOP

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Glofitamab
Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Enasidenib Mesilate
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Idiopathic pulmonary fibrosis

Not recruiting

Study on the Effects and Safety of Buloxibutid for Patients with Idiopathic Pulmonary Fibrosis

Investigational

Study on the Effects and Safety of Buloxibutid for Patients with Idiopathic Pulmonary Fibrosis

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Buloxibutid
Sponsor:Vicore Pharma AB

Contact Research Centre

Cholangiocarcinoma+1

Not recruiting

Study on Gemcitabine and Cisplatin for Patients After Surgery for Bile Duct or Gallbladder Cancer

Registered drugNo placebo

Study on Gemcitabine and Cisplatin for Patients After Surgery for Bile Duct or Gallbladder Cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:University Medical Center Hamburg-Eppendorf

Contact Research Centre

Ovarian cancer

Not recruiting

Study of Olaparib, Durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations

Registered drugNo placebo

Study of Olaparib, Durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Alrefimotide
Sponsor:Nordic Society Of Gynaecological Oncology Clinical Trial Unit

Contact Research Centre

Glomerulonephritis membranoproliferative+1

Not recruiting

Study on the Safety and Effectiveness of Pegcetacoplan for Patients with Post-Transplant Recurrence of C3 Glomerulopathy or Immune Complex Membranoproliferative Nephritis

Registered drugNo placebo

Study on the Safety and Effectiveness of Pegcetacoplan for Patients with Post-Transplant Recurrence of C3 Glomerulopathy or Immune Complex Membranoproliferative Nephritis

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Pegcetacoplan
Sponsor:Apellis Pharmaceuticals Inc.

Contact Research Centre

Circadian rhythm sleep disorder

Not recruiting

Study on the Effects of Tasimelteon for Patients with Delayed Sleep-Wake Phase Disorder

Registered drug

Study on the Effects of Tasimelteon for Patients with Delayed Sleep-Wake Phase Disorder

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Tasimelteon
Sponsor:Vanda Pharmaceuticals Inc.

Contact Research Centre

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in Vienna

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on innovative treatments for various cancer types, including pancreatic ductal adenocarcinoma, gastric cancer, and non-small cell lung cancer. Studies evaluating new therapeutic approaches for breast cancer and multiple myeloma are also underway.

Advanced Cancer Therapies
Targeted Treatment Approaches
Immunotherapy Studies

Research includes evaluation of novel drug combinations and immunotherapy approaches for improved patient outcomes.

02 Neuropsychiatric Studies

Investigations into major depression and its treatment mechanisms, including studies on dopamine synthesis and antidepressant effectiveness. Research examines innovative therapeutic approaches using ketamine and other compounds.

Depression Treatment
Neuroimaging Research
Therapeutic Mechanisms

Focus on understanding brain activation patterns and treatment responses in psychiatric conditions.

03 Autoimmune and Inflammatory Conditions

Research on plaque psoriasis, rheumatic diseases, and Sjögren's syndrome. Studies evaluate new biological therapies and treatment approaches for chronic inflammatory conditions.

Novel Therapeutic Agents
Disease Modification
Long-term Treatment Outcomes

Emphasis on developing targeted therapies for improved disease management and patient quality of life.

Back to Austria All countries